Therapeutic antibodies have a broad development potential. According to relevant data, the market for therapeutic antibody drugs in the world can reach 320 billion US dollars by 2021. The therapeutic antibody drugs have huge market possibility. For innovative antibody research organizations and development enterprises, the success development of antibody drugs is an important goal, and a direction for antibody developers to work on.
But where to start with for a successful development of antibody drugs? The first thing you might think of is the efficacy and side effects of antibody drugs.
While as a medicine, unmet clinical needs are also an important factor that should be considered initially by antibody drug research and development companies and personnel. It is also the starting factor and the foothold of the development of therapeutic antibody drugs.
How do we measure unmet clinical needs? In short, it can be summarized as the following two aspects:
(1) There is currently no treatment for a certain disease;
(2) The current curative effect is not satisfactory or there are side effects that some patients cannot tolerate for the drugs.
Of course, the two aspects can be further refined, and the confirmation of true clinical needs is obtained through a large number of investigations and data analysis. In some extent, it is a huge innovation if antibody drug R&D companies can make differentiated products that truly satisfy and solve clinical needs. If so, it is more likely to be successful in the development of antibody drugs and in the commercialization of later stages.
Whether it is a real clinical need is a comprehensive judgment by the first-line of doctors, patients and others. Some companies have not experienced the above interviews, research and analysis. Based on the investigation of individual doctors and data, they have determined that the products they develop can meet the clinical needs and solve practical problems. In fact, the conclusion is very unobjective.
Why is this important? Because it is a directional problem for innovative pharmaceutical companies, including innovative antibody drug R&D companies. It involves subsequent project strategies and target selection. If the direction is wrong, it is like driving a car to a wrong destination. It is also difficult for the drug development to achieve the final value.
The antibody drug development strategy analyzed above is to address unmet clinical needs, which is a strategic issue. Then how to achieve this goal? Make some differentiated antibody drugs is a tactical problem. After analyzing the FDA approved listing (more than 70 therapeutic antibody drugs) and hundreds of antibody drugs currently in the late stages of clinical development, we can find two important changes in the development:
(1) The side effects of antibody drugs are controllable, and the functions and effects are continuously improved;
(2) The continuous expansion of the target of monoclonal antibody action has expanded to new disease treatment areas and new indications.
Therapeutic antibody drug R&D companies can develop differentiated products that can solve and meet actual clinical needs in the above two aspects. These two aspects are also the key factors to analyze the value of antibody drug R&D companies and related products.
Generate Therapeutic Antibodies with support from the leading global biotech company—Creative Biolabs.
From custom bioreagents to antibody drug developments, Creative Biolabs offers a comprehensive range of services to aid in basic and translational biomedical research as well pharmaceutical research & development.